DGAP-Adhoc: Expedeon AG: Expedeon AG raises adjusted EBITDA guidance for 2019

Ad hoc release according to article 17 MAR
28 October 2019

/

Expedeon AG raises adjusted EBITDA guidance for 2019

Heidelberg, Germany and Cambridge, UK, 28 October 2019 - Expedeon AG (Frankfurt: EXNN; ISIN: DE000A2YN801; Prime Standard) announced today that the Company revised its guidance for the financial year 2019.

With the third quarter 2019, Expedeon AG is expected to reach its full year adjusted EBITDA guidance for 2019 and accordingly raises its full year guidance to EUR 2.5 to 3.0 million (previous guidance: over EUR 2 million). In addition, the Company continues to expect double digit revenue growth for the year.

The revised adjusted EBITDA guidance results in a year-to-year adjusted EBITDA increase of 150 % to 200 % in comparison with the full year 2018 (adjusted EBITDA: EUR 1.0 million).

A definition and explanation of the performance measure adjusted EBITDA can be found on page 27 of the annual report 2018, which is published on the Company's investors' website and accessible at https://investors.expedeon.com/wp-content/uploads/2019/04/Ansicht_4827_2019_Expedeon_Geschaeftsbericht_03_2019_en.pdf.

*** end of ad hoc announcement ***

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO
Phone: +44 1223 873 364
Email: [email protected]
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: [email protected]

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXNN; ISIN: DE000A2YN801).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###